Date:   1/29/2006 1:57:34 PM ( 18 y ago)
Hits:   1,656
URL:   https://www.curezone.org/forums/fm.asp?i=428541

0 of 0 (0%) readers agree with this message.  Hide votes     What is this?

Pfizer's Torcetrapib is clinically proven as a monotherapy for raising HDL (good) Cholesterol (see SCRIP World Pharmaceutical News. April 9, 2004 i2942 p23(1).), but Pfizer is now seeking licening of Torcetrapib in combination with Atorvastatin for the real purpose of protecting Atorvastatin from generic competition.

The bundling of the two drugs together will significantly increase the cost. In addition, many people who would benefit from Torcetrapib will not be able to take this drug because Atorvastatin reacts with many medications.


 

<< Return to the standard message view

fetched in 0.02 sec, referred by http://www.curezone.org/forums/fmp.asp?i=428541